Leaflet NULOJIX 250mg 25mg / ml powder for concentrate for solution for infusion

Product code:
W58734001
Quantity:
1
Indicated for:
prevention of transplant rejection
Route of administration:
infusion
Substance:
belatacept (fusion protein)
ATC
L04AA28 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Selective immunosuppressants
Belatacept is a medication used to prevent organ rejection in patients who have undergone kidney transplantation. It is an immunomodulatory agent that blocks costimulatory signaling required for T-cell activation, thereby reducing the immune response against the transplanted organ.

The medication is administered via intravenous infusion, usually once a month, as directed by a doctor. The treatment requires regular monitoring to assess kidney function and prevent infections.

Common side effects include anemia, infections, high blood pressure, and edema. In rare cases, more severe adverse effects such as post-transplant lymphoproliferative disorder or severe infections may occur.

Belatacept is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions.

General data about NULOJIX 250mg 25mg / ml

Substance:
belatacept
Date of latest medicines list:
01-06-2016
Product code:
W58734001
Concentration:
25mg / ml
Pharmaceutical form:
powder for concentrate for solution for infusion
Quantity:
1
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.